-
Zhengda, Hengrui first on the global TOP50 pharmaceutical companies list (with the world's top 200 drugs list)
Time of Update: 2019-06-14
original title: Zhengda, Hengrui first on the global TOP50 pharmaceutical companies list (with the world's top 200 drugs list) 1 On June 11, 2019, PharmExec, a leading Us magazine, released top 201
-
Heavy, Neng tech plans to sell 75% of ViE to DSM!
Time of Update: 2019-05-28
original title: Heavy Heavyweight, Neng Tech plans to sell 75% of ViE to DSM! in order to save ST Crown, the company's wholly-owned subsidiary, Nengte Technologies, intends to sell a 75% stake in T
-
High uric acidemia huge market, Haitron URAT1 new drug started the first phase of clinical;
Time of Update: 2019-05-22
original title: high uric acidemia huge market, Haitron URAT1 new drug started a clinical phase, a number of domestic research , Chengdu Haitron 1 Drug melt data, PharnexDatamonitor data monitoring
-
Sunny big player: Giofini film, second listed;
Time of Update: 2019-05-22
original title: Tianqing big player: Jifeitinib tablets, the second listing, the competitive landscape intensified 1.5 Gifitinib is a selective epidermal growth factor receptor tyrosine kinase inh
-
A pill touched the hearts of millions of people, drug centralized procurement to you how much money i saved?
Time of Update: 2019-04-18
the original title: a pill to touch the hearts of millions of people, drug centralized procurement to you how much money? through the "packing" "4 plus 7" city procurement volume, the implementatio
-
NASH field: Novo Nordisk Somautide and Gilead strong combination
Time of Update: 2019-04-18
February 19, 2019, Intercept disclosed a phase 3 trial of obetic acid (OCA), which showed that reaching the main endpoint could significantly improve liver fibrosis expect OCA to emerge from the ring and become a precedent for NASH drugs reference: NMPA/CDE; Pharmaceutical Melt data, Pharnex Datamonitor; Drug Melting Current and futurespharmacologicalrapies for NAFLD/NASH Jentergastrool.2018;53 (3): 362-376.
-
LY09004 is approved to enter the clinic, Luye Pharma accelerates global biopharmaceutical layout
Time of Update: 2019-04-03
LVYE Pharmaceutical Group announced that its biological antibody drug ly09004 has been approved by the State Drug Administration to carry out clinical trials In addition to ly09004, LVYE pharmaceutica
-
Anhui line next article: share what has learned to promote development! Mission pool state perfect official!
Time of Update: 2019-03-27
the original title: "Anhui line next" share learning to promote development!
-
Sound water explosion "impact" chemical industry, the following products out of stock price is unstoppable!
Time of Update: 2019-03-27
jiangsu's "3-21" explosion caused more than 70 deaths in , the country's leaders are highly concerned, and even the United Nations Secretary-General Guterres also issued a statement at the United Nations, the accident caused a large number of casualties deeply sad So, do you know how many products will be affected after the Tian Jiayi bombing?
-
Shenzhen will be An Sansa, Jie Kewei and other 6 drugs into the serious illness medical insurance
Time of Update: 2019-03-25
the original title: Shenzhen will Be An Sansa, Jie Kewei and other 6 kinds of drugs into the serious illness medical insurance According to the Guangzhou Daily reported, Shenzhen decided to add six
-
The first "4 plus 7" drug prescription (Entikawe), born in Xiamen!
Time of Update: 2019-03-20
original title: The first "4 plus 7" drug prescription (Entikawe), born in Xiamen ! The original drug price is 175.68 yuan / box (7 tablets / box), and now, The new price of Nitikawe is 8.68 yuan /
-
Stone Pharmaceutical Group: 2018 innovative product performance of 10 billion, growth of 57.2%!
Time of Update: 2019-03-20
original title: Stone Pharmaceutical Group: 2018 innovative product performance broke 10 billion, an increase of 57.2%!
key read: "Stock Market Focus" Stone Medicine have bought over the years what medicine?
-
Overview of the status of consistency evaluation (as of March 9)
Time of Update: 2019-03-12
the original title: The status quo of consistency evaluation (as of March 9) as of March 9, CDE accepted 325 varieties of consistency evaluation, a total of 350 pharmaceutical companies 1055 accept
-
"Heavy first" super antibiotics, phosphatamine approved in our country!
Time of Update: 2019-03-12
original title: "Heavy first" super antibiotics, phosphatamine approved in our country! On March 4, 2019, Bayer Pharmaceuticals' Tedizolidphosphate tablets and injections were approved for the mark
-
These medical and medical enterprises, may go to science and technology board!
Time of Update: 2019-03-07
9 other biopharmaceutical companies that may land on the science and technology board have speculated that there are Fuhong Hanxuan, Sea and Biology, Jiahe Bio, Paige Bio, etc 10 medical-related other enterprises such as Dr Chunyu, Co-effects, World and Genes also do not rule out preparations New Year's blockbuster: 100 Of the domestic Biotech product lines (I) references: Pharmaceutical Melt data, Pharnex Datamonitor; Pharmaceutical melting companies publicly disclosed;
-
Shipharma Group submits application for new drug listing to U.S. for first time
Time of Update: 2019-03-07
original title: Shipharma Group to the United States to submit a new drug listing application is the first time Chinese pharmaceutical companies On March 5, Stone Pharmaceutical S announced that it
-
East Sunshine Drug: $1.626 billion, Acquisition of Large-Volume Generics
Time of Update: 2019-03-05
original title: East Sunshine Medicine: 1.626 billion, the acquisition of large-volume generic drugs East Sunshine group layout is deep, in the field of medicine and health accumulation gradually c
-
Endless! FDA: Shatan gene toxic impurities add new members NMBA! The third one.
Time of Update: 2019-03-05
original title: Endless! FDA: Shatan gene toxic impurities add new members NMBA! A third the FDA update announcement about the recent voluntary recall of a variety of generic angiotensin II recepto
-
2019 New Year's first single! Deqi pharmaceutical completed the financing of 120 million US dollars in round B, and made efforts to lay out the platform for original research and innovation of tumor drugs
Time of Update: 2019-01-08
On January 2, Deqi pharmaceutical announced the completion of a $120 million round B financing This round of financing is jointly led by fountain vest and Boyu capital, with celgene Corporation, Wuxi
-
The first domestic PD-1 has been approved for listing! Facing the price test!
Time of Update: 2018-12-26
On December 17, the State Drug Administration had the conditions to approve the first domestic PD-1 monoclonal antibody - treprizumab injection (trade name: tuoyi) It took 284 days from submitting the
